Sociedad Americana de Hirudoterapia

Ministry of Health and Medical Services — Solomon Islands

Solomon Islands MHMS · Solomon Islands · oceania

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Solomon Islands' MHMS — leech-specific authorisation pathway not independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
oceania
Country
Solomon Islands
Leech status
unregulated
Last ASH review
2026-05-28

Relevant Regulation Codes

  • Solomon Islands Pharmacy and Poisons Act Cap. 109 and amendments
  • Pacific Island Countries (PIC) joint procurement arrangements through the Pacific Pharmaceutical Procurement Service where applicable

Prescriber Requirements

  • Solomon Islands Medical Board–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Solomon Islands MHMS registration as applicable; English and Solomon Islands Pijin-language labelling per local convention. Standard cold-chain conditions, with logistical constraints typical of Melanesian archipelago distribution.

Import/Export Rules

Solomon Islands MHMS and Biosecurity Solomon Islands clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Solomon Islands' public health system coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific authorisation pathway not independently verified by ASH; falls under general medical-device / traditional-medicine framework as appropriate. Pacific island nations frequently rely on Australian TGA, New Zealand Medsafe and WHO-prequalified products via Pacific cooperation arrangements.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.